- Home
- ASIC vs NBTX Comparison
ASIC vs NBTX Comparison
Compare ASIC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASIC | NBTX |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.2M | 1.0B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ASIC | NBTX |
|---|---|---|
| Price | $18.77 | $21.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $25.25 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 84.7K | 16.3K |
| Earning Date | 02-19-2026 | 09-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 504.00 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $405,657,000.00 | $11,930,711.00 |
| Revenue This Year | $14.72 | N/A |
| Revenue Next Year | $44.71 | $145.24 |
| P/E Ratio | $107.54 | ★ N/A |
| Revenue Growth | ★ 68.10 | N/A |
| 52 Week Low | $16.35 | $2.95 |
| 52 Week High | $25.30 | $30.35 |
Technical Indicators
Market Signals| Indicator | ASIC | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 48.55 |
| Support Level | $17.49 | $21.03 |
| Resistance Level | $19.18 | $22.15 |
| Average True Range (ATR) | 0.73 | 0.63 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 74.29 | 46.98 |
Price Performance
Historical ComparisonAbout ASIC Ategrity Specialty Insurance Company Holdings
Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.